EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum zinc as a biomarker to predict the efficacy of immune checkpoint inhibitors in cancers

Jingliang Wang, Weihao Wang, Bin Liu, Rui Zhao, Jing Zhao, Fengxian Jiang, Wei Xu, Zhizhao Zhang, Pancen Ran, Yang Shu, Yahui Wang, Liying Pan und 3 weitere

PLOS One · 03.07.2025 · 20 (7) · e0326057

DOI: 10.1371/journal.pone.0326057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 03.07.2025. Verfasst von Jingliang Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Zinc, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taishan Scholar Foundation of Shandong Province, National Natural Science Foundation of China, 2021 Shandong Medical Association Clinical Research Fund [.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study was to investigate whether serum zinc levels correlate with the response to immune checkpoint inhibitors (ICIs) and whether they can be used as a useful prognostic biomarker in patients with advanced or metastatic cancer.

Methods

We divided 98 patients with advanced or metastatic lung, esophageal, gastric, and colorectal cancer into two groups based on enrollment date: the training group (n = 68) and the validation group (n = 30). And these patients were from Shandong Provincial Hospital and had received immunotherapy. We then used the solid tumor response Evaluation Criteria (RECIST v1.1) to determine whether the patient’s condition was evaluated for clinical benefit response (CBR) or non-clinical benefit (NCB). Subsequently, serum zinc levels were assessed using ICP-MS.

Results

We have identified for the first time that elevated levels of serum zinc (>14.2μg/L) in cancer patients undergoing immunotherapy can serve as a novel biomarker for improved overall survival (20.0m vs 10.0m; p < 0.0001), as determined by continuous serum zinc data using ROC curve analysis (sensitivity: 100.00%, specificity: 41.86%, p = 0.0009) in both CBR (n = 43) and NCB patients (n = 25) within the training group. Bioinformatics analysis has revealed that serum zinc may modulate cellular DNA replication through the MAPK and NF-kB pathways, with proteomic analysis confirming enrichment of these pathways based on KEGG and GO analyses. Consequently, a nomogram incorporating multiple clinical and independent factors has been developed to provide enhanced predictive capability.

Conclusions

Serum zinc levels are positively associated with the effectiveness of ICIs in patients with advanced or metastatic cancer, potentially through their modulation of NF-κB and MAPK pathways. These findings highlight serum zinc as a valuable biomarker for predicting responses to ICI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsZincBiomarkers, TumorNeoplasmsHumansFemaleMaleMiddle AgedAgedPrognosisAdultTreatment Outcome

Substanzen

Immune Checkpoint InhibitorsZincBiomarkers, Tumor

Autor:innen und Institutionen

  • The Second Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Department of Biomedical Engineering, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Department of Oncology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
  • Department of Oncology, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

ORCID-Profile: Guobin Fu

Förderung

  • Taishan Scholar Foundation of Shandong Province
  • National Natural Science Foundation of China
  • 2021 Shandong Medical Association Clinical Research Fund [
  • Natural Science Foundation of Shandong Province
  • Key Development Program of Shandong Province
  • Beijing Xisike Clinical Oncology Research Foundation
  • Health Commission of Shandong Province

Zitieren

APA

Wang, J., Wang, W., Liu, B., Zhao, R., Zhao, J., Jiang, F., Xu, W., Zhang, Z., Ran, P., Shu, Y., Wang, Y., Pan, L., Liu, L., Luan, F., & Fu, G. (2025). Serum zinc as a biomarker to predict the efficacy of immune checkpoint inhibitors in cancers. PLOS One, 20(7), e0326057. https://doi.org/10.1371/journal.pone.0326057

Vancouver

Wang J, Wang W, Liu B, Zhao R, Zhao J, Jiang F, et al. Serum zinc as a biomarker to predict the efficacy of immune checkpoint inhibitors in cancers. PLOS One. 2025;20(7):e0326057. doi:10.1371/journal.pone.0326057

BibTeX
@article{Wang2025,
  author = {Wang, Jingliang and Wang, Weihao and Liu, Bin and Zhao, Rui and Zhao, Jing and Jiang, Fengxian and Xu, Wei and Zhang, Zhizhao and Ran, Pancen and Shu, Yang and Wang, Yahui and Pan, Liying and Liu, Lei and Luan, Fang and Fu, Guobin},
  title = {Serum zinc as a biomarker to predict the efficacy of immune checkpoint inhibitors in cancers},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {7},
  pages = {e0326057},
  doi = {10.1371/journal.pone.0326057}
}
Kostenlos starten →